Up and Coming

Up and Coming from AVROBIO, Lysogene and ReViral

October 28, 2019

This feature highlights changes in clinical research organizations’ personnel.

Suzanne Winter has been appointed senior vice president and chief commercial officer at Accuray. Winter was formerly group vice president for the Americas region at Medtronic Diabetes.

Achilles Therapeutics
Beverly Carr has been appointed chief business officer at Achilles Therapeutics. Carr was most recently vice president of business development for the immune-inflammation therapy area at GlaxoSmithKline.

AMD Medicom
AMD Medicom named Guillaume Laverdure president of North America and Ouriel Levy executive vice president of commercial and global president of dental. Laverdure is currently chief operating officer at the company and will continue in that role. Levy is the former corporate vice president of sales for A.R. Medicom.

AVROBIO has appointed Holly May chief commercial officer. May was most recently vice president and head of commercial at SOBI.

BlackThorn Therapeutics
BlackThorn Therapeutics has named William Martin chief executive officer. Martin most recently served as president and chief operating officer as well as the chief scientific officer of BlackThorn.

Cadent Therapeutics
Cadent Therapeutics has appointed Christopher Kenney chief medical officer and Dawn Williams as vice president of clinical operations. Kenney last served as senior vice president of medical affairs at Acorda Therapeutics. Williams was most recently vice president of clinical operations and program management at Albireo Pharma.

Beth Landry has been appointed the first chief operating officer at Caregiver. Landry previously served as senior vice president of operations at Seniorlink.

Clinical Laserthermia Systems Americas
Micahel Magnani has been named managing director for the U.S. and North America at Clinical Laserthermia Systems Americas. Magnani previously served as the chief executive officer of StimAire.

Harvard Bioscience
Ken Olson has been named vice president and general manager for pre-clinical systems at Harvard Bioscience. Olson was previously senior vice president of global engineering and operations at Spacelabs Healthcare.

HepaRegeniX GmbH
HepaRegeniX GmbH has named Michael Lutz chief executive officer and managing director of the company. Lutz formerly served as CEO of LifeCodexx AG.

Kintai Therapeutics
Kintai Therapeutics has appointed Francesca Barone head of experimental medicine. Barone was most recently a reader and academic head of business engagement for the college of medical and dental science at the University of Birmingham.

LifeMine Therapeutics
Iain McFayden has been named chief data officer, Jared Cumming senior vice president and head of chemistry and Dawn Thompson vice president and head of microbiology and automation at LifeMine Therapeutics. Previously, McFayden served as head of computational sciences and next generation analytics at Moderna. Cumming most recently served as executive director of chemistry at Merck. Prior to joining LifeMine, Thompson was chief scientific officer at Directed Genomics.

Stéphane Durant des Aulnois was named chief financial officer at Lysogene. Durant des Alunois recently served as vice president and head of investor relations at the company.

MediSpend has named Seth Houston chief commercial officer. Before joining the company, Houston served as managing director of IQVIA’s U.S. technology solutions business unit.

Medtronic plc has named Sean Salmon executive vice president and group president of Medtronic Diabetes. Salmon was recently president of coronary and structural heart within the cardiac and vascular group at Medtronic.

Moberg Pharma
Moberg Pharma has appointed Mark Beveridge as vice president of finance. Beveridge was most recently senior advisor in accounting for the company.

Myriad Genetics
Myriad Genetics has named Mark Pollack chief medical officer of Myriad Neuroscience. Pollack served as a professor and chair of the department of psychiatry at Rush University Medical Center in Chicago and as a professor at Harvard Medical School’s center for anxiety and traumatic stress disorders.

Alice Shaw has been named lead of translational clinical oncology at Novartis. Shaw is a professor of medicine at Harvard Medical School and an attending physician in the Thoracic Cancer Program at Massachusetts General Hospital.

On Target Laboratories
Kimberly Fabrizio has been appointed vice president of regulatory and quality at On Target Laboratories. Fabrizio previously held the position of vice president of regulatory affairs and compliance at Invicro.

John McCabe was named chief financial officer at Oncorus. Previously, McCabe was CEO of Flex Pharma, now known as Salarius Pharmaceuticals.

Pharmavite has expanded its leadership team with the addition of Rhonda Hoffman as chief marketing officer. Hoffman previously served as CMO at Elanco Animal Health.

Alan Musso has been named chief financial officer of ReViral. Musso was formerly CFO at Peloton Therapeutics.

Rheos Medicines
Rheos Medicines has named Barbara Fox chief executive officer. Fox was most recently CEO at Tilos Therapeutics.

Smith & Nephew
Roland Diggelmann has been named chief executive officer of Smith & Nephew. Diggelmann is the former CEO at Roche Diagnostics.

Stéphane Baudouin has been appointed chief of science at STALICLA. Baudouin was senior lecturer and team leader at Cardiff University.

Sumitomo Dainippon Pharma
Shigeyuki Nishinaka was named executive officer of global business development, international business management senior director and global business development at Sumitomo Dainippon Pharma. Nishinaka previously held the position of executive officer of global business development and international business management at the company.

TLC has named Vincent Chang vice president of manufacturing and development. Chang was previously managing director of YiLi Consulting, LLC.

Versameb AG
Versameb AG has named Isabel Ferreira chief business officer. Ferreira was previously with Roche where she served as director of global business and development.